Methods: Non-duplicate strains were consecutively collected from five medical centres in 5 states using isolates from bacteraemia (n = 253), pneumonia (n = 146), complicated skin and skin structure infections (n = 264), and other infections (n = 269). All isolates were tested against tigecycline using validated commercial reference broth microdilution panels (TREK Diagnostics), with concurrent quality controls and CLSI (M100-S18) interpretations for comparison agents. Tigecycline breakpoints published by the US-FDA were applied for each indicated species or genus group.
Objectives: Worldwide the prevalence of MDR Enterobacteriaceae are increasing, including ESBLs, AmpC, fluoroquinolone and carbapenem resistant strains. The T.E.S.T. program determined the in vitro activity of tigecycline compared to amoxicillin-clavulanic acid, piperacillintazobactam, levofloxacin, ceftriaxone, cefepime, ampicillin, amikacin, minocycline, ceftazidime and imipenem against Enterobacteriaceae species collected from hospitals in Asia/Pacific Rim 2004 -2007 . This study evaluated the activity of tigecycline against multi-resistant microorganisms associated with nosocomial infections.
Methods: A total of 2778 clinical isolates were identified to the species level at each site and confirmed by the central laboratory. Minimum Inhibitory Concentration (MICs) were determined by each site using supplied broth microdilution panels and interpreted according to CLSI guidelines. Tigecycline breakpoint is defined as susceptible MICs ≤2 mcg/mL 
Aim: To assess the antimicrobial resistance patern in pathogens responsible for urinary tract infections in nosocomial patients over a period of one year.
Material and Method: From January 2006 to December 2006, 3665 urine cultures from nosocomial patients were collected. All positive cultures with a colony count ≥105 CFU/ml for Gram-positive and Gram-negative bacteria and ≥103 CFU/ml for Candida species were selected for the analysis. Duplicate isolates were not considered Results: Among the 757 positive cultures n = 135 belonged to I.C.U., n = 58 to Surgical Dept, n = 347 to Internal Medicine Dept and n = 217 to Outpatien Dept. Among the 757 positive cultures n = 523 belonged to female and n = 234 to 13th International Congress on Infectious Diseases Abstracts, Poster Presentations e413 male patients. Among the Gram-negative Escherichia coli n = 337 presented the highest prevalence, followed by Proteus mirabilis n = 97, Pseudomonas aeruginosa n = 67, Candida species n = 65, Klebsiella pneumoniae n = 45 and Acinetobacter baumannii n = 22. Among Gram positive isolates Enterococcus faecalis was the most prevalence n = 28, followed by coagulase negative staphylococci n = 16, Enterococcus faecium n = 11 and Staphylococcus aureus n = 5. They were 4 VRE strains (Enterococcus faecium) in the urine. All Gram positive cocci were sensitive to linezolide. Resistance rates to Gram-negative are presented. All Gram-negative were susceptible to colistin. All strains of Acinetobacter baumannii were susceptible to doxycyclin while they appeared susceptible to ampicillin/sulbactam to a percentage of 90%. The largest number of fungus positive samples were taken from the Internal medicine departments
Conclusions: Escherichia coli is the primary bacterial pathogen causing UTIs in nosocomial patients. Candida albicans was isolated from the majority of the samples, compared to non albicans. 
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Impact of Educational Efforts on Antimicrobial Prescribing and Bacterial Resistance Rates in a Community Hospital
O.H. DeTorres
Palomar Medical Center, Escondido, CA, USA Purpose: The prescribing of quinolones in the outpatient setting has resulted in widespread quinolone resistance among gram-negative organisms. Because of this, quinolones should no longer be used as empiric therapy in the management of urinary tract infections within our hospitals. The objectives of this study were to evaluate how educational efforts would impact antimicrobial prescribing in the treatment of urinary tract infections and whether the change in prescribing habits would result in a change in bacterial susceptibilities to quinolones within our hospitals.
Methods: Data was collected on all hospitalized patients admitted with a diagnosis of urinary tract infections, urosepsis, or pyelonephritis (n = 113) during January -May 2005. Antimicrobials selected for empiric and targeted therapy were reviewed. Twenty-nine percent of communityacquired infections and 41.2% of institutionally-acquired infections were found to be resistant to the quinolones, while only 15.6% and 17.1% of the respective infections were resistant to cefazolin. The results were presented to the Antibiotic Subcommittee of the Pharmacy & Therapeutics Committee, Emergency Medicine Department, and hospitalists physician group. This was followed by an article published in the physician newsletter on the management of urinary tract infections. Empiric prescribing guidelines encouraging the use of cefazolin were incorporated into the system-wide antibiogram. Educational posters were created and displayed at all of the nursing units and Emergency Rooms. A follow-up study was conducted in January -March 2007 (n = 75) to evaluate the impact of the educational efforts on antibiotic prescribing. Finally, the bacterial susceptibilities were compared before and after the educational efforts. A 22-year-old male army officer cadet presented with a three day history of high fever, cough with haemoptysis, sore throat, myalgia and severe diarrhoea. Investigations on admission showed a normal total white cell count, hyponatraemia, a raised creatine kinase, pyuria and a normal chest radiograph. He was administered oral ciprofloxacin for three days with no resolution of fever or symptoms. Repeat chest radiograph done on Day 4 of admission showed multilobar pneumonia with worsening of laboratory results. Antibiotic therapy was changed to intravenous penicillin, ceftazidime and azithromycin. His fever and symptoms resolved promptly within 48 hours. Subsequent serological studies revealed a nine-fold increase in Mycoplasma pneumoniae antibody titre, and the patient was diagnosed with Mycoplasma pneumonia. Ciprofloxacin is generally considered as an effective treatment against Mycoplasma pneumoniae based on in-vitro susceptibility to ciprofloxacin. Till date there has been only one case report of its effective use (Masayoshi et al. Antibiotics and Chemotherapy. 18(12) , p1835-1839 Japanese). This case report is the first in the literature to suggest clinical failure. Ciprofloxacin may not be effective in the treatment of Mycoplasma pneumonia. Background: It is a common knowledge that antibiotics are used indiscriminately. They should be used for actual infections and not for colonization or prolonging the
